Corden Pharma Experts taking care. APIs DRUG PRODUCTS FACILITIES PLATFORMS ABOUT US CONTACT US Peptisyntha Home Facilities Brussels, BE Peptisyntha Managing Director: Piet Serrure Peptisyntha SA 310 rue de Ransbeek 1120 Brussels Belgium Email Contact: sales@cordenpharma.com Human Resources Contact: HR@peptisyntha.com Phone:+32 2 263 1411 Get Driving Directions: GET DIRECTIONS >>> New Brochure <<< Click here to read CordenPharma Peptisyntha's new brochure Core Capabilities Solid-phase peptide synthesis (SPPS) Liquid-phase peptide synthesis (LPPS) Hybrid strategies (SPPS-LPPS) Complex peptides and peptidomimetics Peptide-conjugations (PEGs, proteins, lipids, carbohydrates) Cyclic peptides & peptides with multiple disulfide bridges Short peptides (10-12 residues), often with no HPLC purification Arginine-rich peptides Peptisyntha Facility Capacities Compliance Approvals 5 FDA inspections: Most recently January 2013 with no 483 Form 2011: Belgian Health Authorities on behalf of EMA DMF filing experience: USA, Europe, Japan, Australia, Canada, New Zealand Facility Legacy Founded in 1987, Peptisyntha was a member of the Solvay group until being acquired by CordenPharma in October 2013. Peptisyntha has built 26 year track record of success in supplying pharmaceutical and biotech companies with small to commercial scale cGMP peptide API manufacturing using world-class cost-effective production processes. Through expertise and capabilities in all synthetic manufacturing technologies, Peptisyntha assesses and customized their manufacturing approach to achieve the most effective manufacturing process for their customers. Peptisyntha has developed a portfolio of innovative proprietary technologies with the objective to shorten synthetic processes / reduce the number of steps, control quality, and simplify (or eliminate) HPLC purifications for short peptides. History 1987: Peptisyntha founded on the Solvay Campus 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market 2001: Completion of production plant extension 2006-2008: Additional capabilities, further kilo-lab capacity, new QC/microbiology labs, new warehouse 2011: Solid-phase peptide production units added 2013: FDA inspection, no 483 form. Total of 5 successful FDA inspections October 2013: Peptisyntha acquired by ICIG (International Chemical Investor Group) to join CordenPharma Facilities Bergamo, IT Brussels, BE Caponago, IT Chenôve, FR Colorado, US Latina, IT Plankstadt, DE Liestal, CH Resource Library » Standard Catalog Products Brochures Corden Pharma Corden Pharma International GmbH, Otto-Hahn-Strasse, 68723 Plankstadt, Germany sales@cordenpharma.com ©2012 CordenPharma International Media Contact Impressum Terms and Conditions Privacy Policy Website by Boston Interactive Facebook LinkedIn APIs API Development API Contract Manufacturing Generic API Manufacturing Highly Potent APIs Sterile APIs Peptides Building Blocks Conjugate Products Carbohydrates Derivatized Phospholipids Support Services Drug Products Drug Product Development Drug Product Contract Manufacturing Generic Drug Manufacturing Sterile Formulation Highly Potent Formulation Oncology Cephalosporin Manufacturing Penicillin Manufacturing Parenterals Large Pre-Filled Syringes Sterile Oncology Oral Oncology Two-layer tablets Clinical Supply Services Packaging Pharma-Logistics Support Services Facilities Bergamo, IT Brussels, BE Caponago, IT Chenôve, FR Colorado, US Latina, IT Plankstadt, DE Liestal, CH Platforms Antibiotic / Oncology High Potent / Small Molecule Peptide / Injectable About Us Our History Compliance News and Press Events ICIG Careers Contact Us